Tanaka H, et al. - Researchers investigated the long-term retention rate as well as the prognostic factors related to the discontinuation of adalimumab therapy in patients with Crohn's disease who had received at least 1 induction dose of 160 mg of adalimumab between October 2010 and December 2013. The following were discovered to be the significant independent predictors of poor retention rate of adalimumab treatment: Female sex, previous infliximab use, perianal disease, concomitant treatment with prednisolone at baseline, higher C-reactive protein levels, and lower albumin levels. Owing to adverse events, especially skin reactions, infections, and arthralgia, more female patients compared to male patients discontinued adalimumab. A good retention rate of adalimumab was unveiled among patients with Crohn's disease over a 4 year period.